Letrozole and palbociclib in advanced breast cancer: Outcome from cancer institute, Chennai
Background: Cyclin-dependent kinase 4/6 inhibitor addition to hormonal therapy has shown to improve the survival of hormone receptor (HR)-positive, HER2-negative advanced breast cancer (ABC). Methods: We retrospectively analyzed untreated patients with HR-positive, HER2-negative ABC, who received le...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Thieme Medical and Scientific Publishers Pvt. Ltd.
2020-01-01
|
| Series: | Indian Journal of Medical and Paediatric Oncology |
| Subjects: | |
| Online Access: | http://www.ijmpo.org/article.asp?issn=0971-5851;year=2020;volume=41;issue=2;spage=182;epage=186;aulast= |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849701906591514624 |
|---|---|
| author | Vijay Gnanaguru Manikandan Dhanushkodi Venkatraman Radhakrishnan Jayachandran Perumal Kalaiarasi Nikita Mehra Archit Joshi Arun Kumar Rajan Gangothri Selvarajan Parathan Karunakaran Balasubramanian Ananthi Priya Iyer Geetha Senguttuvan Manjula Rao Madhu Priya Arvind Krishnamurthy Sridevi Velusamy Hemanth Raj Rama Ranganathan Shirley Sundersingh Krishna Kumar Selvaluxmy Ganesarajah Trivadi S Ganesan Tenali Gnana Sagar |
| author_facet | Vijay Gnanaguru Manikandan Dhanushkodi Venkatraman Radhakrishnan Jayachandran Perumal Kalaiarasi Nikita Mehra Archit Joshi Arun Kumar Rajan Gangothri Selvarajan Parathan Karunakaran Balasubramanian Ananthi Priya Iyer Geetha Senguttuvan Manjula Rao Madhu Priya Arvind Krishnamurthy Sridevi Velusamy Hemanth Raj Rama Ranganathan Shirley Sundersingh Krishna Kumar Selvaluxmy Ganesarajah Trivadi S Ganesan Tenali Gnana Sagar |
| author_sort | Vijay Gnanaguru |
| collection | DOAJ |
| description | Background: Cyclin-dependent kinase 4/6 inhibitor addition to hormonal therapy has shown to improve the survival of hormone receptor (HR)-positive, HER2-negative advanced breast cancer (ABC). Methods: We retrospectively analyzed untreated patients with HR-positive, HER2-negative ABC, who received letrozole and palbociclib at the Cancer Institute, Chennai, from October 2017 to January 2019. Results: A total of 24 patients were included in this study. The median progression-free survival (PFS) was 18 months, and the median overall survival (OS) had not reached. The 1-year PFS and OS were 73.7% and 89.2%, respectively. The common toxicities were neutropenia and fatigue but none of the patients had febrile neutropenia. Conclusion: Letrozole-Palbociclib is effective with manageable toxicity as the first-line treatment for HR-positive, HER2-negative ABC. |
| format | Article |
| id | doaj-art-23d36085e34c4bbea16bb6b65f59b5f7 |
| institution | DOAJ |
| issn | 0971-5851 0975-2129 |
| language | English |
| publishDate | 2020-01-01 |
| publisher | Thieme Medical and Scientific Publishers Pvt. Ltd. |
| record_format | Article |
| series | Indian Journal of Medical and Paediatric Oncology |
| spelling | doaj-art-23d36085e34c4bbea16bb6b65f59b5f72025-08-20T03:17:51ZengThieme Medical and Scientific Publishers Pvt. Ltd.Indian Journal of Medical and Paediatric Oncology0971-58510975-21292020-01-0141218218610.4103/ijmpo.ijmpo_156_19Letrozole and palbociclib in advanced breast cancer: Outcome from cancer institute, ChennaiVijay GnanaguruManikandan DhanushkodiVenkatraman RadhakrishnanJayachandran Perumal KalaiarasiNikita MehraArchit JoshiArun Kumar RajanGangothri SelvarajanParathan KarunakaranBalasubramanian AnanthiPriya IyerGeetha SenguttuvanManjula RaoMadhu PriyaArvind KrishnamurthySridevi VelusamyHemanth RajRama RanganathanShirley SundersinghKrishna KumarSelvaluxmy GanesarajahTrivadi S GanesanTenali Gnana SagarBackground: Cyclin-dependent kinase 4/6 inhibitor addition to hormonal therapy has shown to improve the survival of hormone receptor (HR)-positive, HER2-negative advanced breast cancer (ABC). Methods: We retrospectively analyzed untreated patients with HR-positive, HER2-negative ABC, who received letrozole and palbociclib at the Cancer Institute, Chennai, from October 2017 to January 2019. Results: A total of 24 patients were included in this study. The median progression-free survival (PFS) was 18 months, and the median overall survival (OS) had not reached. The 1-year PFS and OS were 73.7% and 89.2%, respectively. The common toxicities were neutropenia and fatigue but none of the patients had febrile neutropenia. Conclusion: Letrozole-Palbociclib is effective with manageable toxicity as the first-line treatment for HR-positive, HER2-negative ABC.http://www.ijmpo.org/article.asp?issn=0971-5851;year=2020;volume=41;issue=2;spage=182;epage=186;aulast=advanced breast cancerletrozolepalbociclib |
| spellingShingle | Vijay Gnanaguru Manikandan Dhanushkodi Venkatraman Radhakrishnan Jayachandran Perumal Kalaiarasi Nikita Mehra Archit Joshi Arun Kumar Rajan Gangothri Selvarajan Parathan Karunakaran Balasubramanian Ananthi Priya Iyer Geetha Senguttuvan Manjula Rao Madhu Priya Arvind Krishnamurthy Sridevi Velusamy Hemanth Raj Rama Ranganathan Shirley Sundersingh Krishna Kumar Selvaluxmy Ganesarajah Trivadi S Ganesan Tenali Gnana Sagar Letrozole and palbociclib in advanced breast cancer: Outcome from cancer institute, Chennai Indian Journal of Medical and Paediatric Oncology advanced breast cancer letrozole palbociclib |
| title | Letrozole and palbociclib in advanced breast cancer: Outcome from cancer institute, Chennai |
| title_full | Letrozole and palbociclib in advanced breast cancer: Outcome from cancer institute, Chennai |
| title_fullStr | Letrozole and palbociclib in advanced breast cancer: Outcome from cancer institute, Chennai |
| title_full_unstemmed | Letrozole and palbociclib in advanced breast cancer: Outcome from cancer institute, Chennai |
| title_short | Letrozole and palbociclib in advanced breast cancer: Outcome from cancer institute, Chennai |
| title_sort | letrozole and palbociclib in advanced breast cancer outcome from cancer institute chennai |
| topic | advanced breast cancer letrozole palbociclib |
| url | http://www.ijmpo.org/article.asp?issn=0971-5851;year=2020;volume=41;issue=2;spage=182;epage=186;aulast= |
| work_keys_str_mv | AT vijaygnanaguru letrozoleandpalbociclibinadvancedbreastcanceroutcomefromcancerinstitutechennai AT manikandandhanushkodi letrozoleandpalbociclibinadvancedbreastcanceroutcomefromcancerinstitutechennai AT venkatramanradhakrishnan letrozoleandpalbociclibinadvancedbreastcanceroutcomefromcancerinstitutechennai AT jayachandranperumalkalaiarasi letrozoleandpalbociclibinadvancedbreastcanceroutcomefromcancerinstitutechennai AT nikitamehra letrozoleandpalbociclibinadvancedbreastcanceroutcomefromcancerinstitutechennai AT architjoshi letrozoleandpalbociclibinadvancedbreastcanceroutcomefromcancerinstitutechennai AT arunkumarrajan letrozoleandpalbociclibinadvancedbreastcanceroutcomefromcancerinstitutechennai AT gangothriselvarajan letrozoleandpalbociclibinadvancedbreastcanceroutcomefromcancerinstitutechennai AT parathankarunakaran letrozoleandpalbociclibinadvancedbreastcanceroutcomefromcancerinstitutechennai AT balasubramanianananthi letrozoleandpalbociclibinadvancedbreastcanceroutcomefromcancerinstitutechennai AT priyaiyer letrozoleandpalbociclibinadvancedbreastcanceroutcomefromcancerinstitutechennai AT geethasenguttuvan letrozoleandpalbociclibinadvancedbreastcanceroutcomefromcancerinstitutechennai AT manjularao letrozoleandpalbociclibinadvancedbreastcanceroutcomefromcancerinstitutechennai AT madhupriya letrozoleandpalbociclibinadvancedbreastcanceroutcomefromcancerinstitutechennai AT arvindkrishnamurthy letrozoleandpalbociclibinadvancedbreastcanceroutcomefromcancerinstitutechennai AT sridevivelusamy letrozoleandpalbociclibinadvancedbreastcanceroutcomefromcancerinstitutechennai AT hemanthraj letrozoleandpalbociclibinadvancedbreastcanceroutcomefromcancerinstitutechennai AT ramaranganathan letrozoleandpalbociclibinadvancedbreastcanceroutcomefromcancerinstitutechennai AT shirleysundersingh letrozoleandpalbociclibinadvancedbreastcanceroutcomefromcancerinstitutechennai AT krishnakumar letrozoleandpalbociclibinadvancedbreastcanceroutcomefromcancerinstitutechennai AT selvaluxmyganesarajah letrozoleandpalbociclibinadvancedbreastcanceroutcomefromcancerinstitutechennai AT trivadisganesan letrozoleandpalbociclibinadvancedbreastcanceroutcomefromcancerinstitutechennai AT tenalignanasagar letrozoleandpalbociclibinadvancedbreastcanceroutcomefromcancerinstitutechennai |